KITLG and gastric cancer: In conclusion, our study revealed that apatinib exhibited synergistic antitumor effects with pyrotinib and reversed acquired pyrotinib resistance in HER2-positive GC by targeting the SCF/c-kit/PI3K/AKT and SCF/c-kit/MAPK signaling pathways (Fig. 6g).